IMPLANET announces consolidated turnover of 5.8 million euros as of September 30, 2021, up 34%


BORDEAUX, France & BOSTON – (COMMERCIAL THREAD) – Regulatory news:

IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME) (Paris: ALIMP) medical technology company specializing in spinal and knee surgery implants, today announces its sales for the third quarter and nine first months of the year on September 30, 2021.

Ludovic Lastennet, CEO of IMPANET, noted: “These third quarter results confirm the growth momentum in our sales since the start of 2021, despite a health context and a shortage of hospital staff which are still hampering a return to normal activity. While supporting this recovery by meeting the expectations of surgeons, we are continuing to refocus our activity on the spine, initiated with the acquisition of OSD in May. The recently announced plan to sell our Knee activity will enable IMPLANET to establish itself as a benchmark player in spine surgery, both in France and abroad, while consolidating its current financial situation. With these additional resources, we will intensify and accelerate our business development, enrich our range of spinal implants and continue to expand our certifications and accreditations over the coming months.”.

In thousands of euros – IFRS1



Switch %

Total 1st quarterly sales



+ 7%

Total 2sd quarterly sales



+ 98%

3rd trimester



1 194

+ 49%





Total 3rd quarterly sales

2 112


+ 21%

9-month turnover



2 704

+ 61%





Total revenue over 9 months

5 830


+ 34%

Third quarter 2021

IMPANET’s refocusing on its Spine activity and the integration of OSD since May 19, 2021 enabled the Company to generate 49% growth in Spine revenue in Q3 compared to the same quarter of 2020.

In France, Spine’s activity doubled compared to the third quarter of 2020 (and the same quarter of 2019), with a turnover of 0.75 M €. In the United States, the postponement of the quarterly order from the Company’s partner, SeaSpine, and numerous surgeries treated directly negatively impacted the activity over the period, with sales down 36% compared to the third quarter 2020, at € 0.41m. In the rest of the world, turnover has multiplied by almost 3.5 compared to the same period of 2020 (+ 235%) and by more than 2.5 compared to 2019 (+ 160%), at € 0.62m.

MADISONMT activity was down compared to the third quarter of 2020, at 0.34 million euros. This is mainly due to the public health situation and the postponement of this type of surgery due to human resource issues in health facilities.

First nine months of 2021

In total, over the nine months to the end of September 2021, IMPLANET achieved a turnover of 5.83 M €2, up 34% compared to the first 9 months of 2020 and + 5% compared to the same period of 2019.

Thanks to the acquisition of OSD in the first half of 2021, the Spine activity generated a strong increase in turnover of 61% compared to 2020, to 4.35 million euros. This activity is also up 22% compared to 2019.

Highlights from 2021 to date

  • Agreement for the acquisition of OSD, specializing in the development, manufacture and marketing of implants for spinal surgery;

  • Liquidation for MADISONMT total knee replacement obtained from the TGA (Therapeutic Goods Administration) allowing the product to be marketed in Australia;

  • Signature of a strategic partnership with ulrich medical® for the distribution of JAZZ® implants and the OSD cervical plate;

  • Exclusive distribution contract with GLOBUS MEDICAL to market the latter’s scoliosis correction system to 15 French university centers specializing in pediatric spine surgery in order to increase our market share;

  • Planned divestment of MADISONMT the knee prosthesis company to refocus to become a benchmark player in spinal surgery.

A webinar will take place at 6:00 p.m. CEST today, October 12, 2021

The Company wishes to inform its shareholders that a webinar will be organized at 6 p.m. (Paris time) today.

During this web conference, Ludovic Lastennet, Managing Director, and David Dieumegard, Financial Director, will be at your disposal to discuss:

– improvement in the 2021 half-year results;

– sales for the third quarter of 2021;

– the proposed sale of MADISONMT knee prosthesis business;

– and the strategic axes of the development plan.

The webinar will be in French and will be followed by a question and answer session.

To follow this webinar, simply log in via the following link:

Next financial event:

2021 annual turnover, January 18, 2022 after market *

* Date subject to change


Founded in 2007, IMPLANET is a medical technology company that manufactures high quality implants for orthopedic surgery. Its activity revolves around two product ranges, an innovative global solution to improve the treatment of spinal pathologies (JAZZ® and OSD), as well as the MADISON implant for first-line prosthetic knee surgery. Implanet’s proven orthopedic platform is based on the traceability of its products. Protected by four international patent families, JAZZ® has obtained 510 (k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, CE marking in Europe and ANVISA approval in Brazil. IMPLANET employs 29 people and achieved a turnover of 6.0 million euros in 2020. For more information, visit Based near Bordeaux in France, IMPLANET opened an American subsidiary in Boston in 2013. In May 2021, IMPLANET acquired Orthopedic & Spine Development (OSD), specializing in the development, manufacture and marketing of implants for surgery of the breast. spine and offers a range of products that complements the latest generation JAZZ® implant (thoraco-lumbar screws, cages and cervical plates). IMPLANET is listed on the Euronext Growth market in Paris.

The Company reminds readers that the monitoring table for the equity line (OCA, BSA) and the number of shares in circulation is available on its website:

1 Unaudited data

2 Since May 19, 2021, the Spine activity has included the turnover recorded by OSD, i.e. € 1.17 million.

Source link

Leave A Reply

Your email address will not be published.